PDGF AA (PDGFA) Rabbit Polyclonal Antibody

CAT#: TA328415

Anti-Human PDGF-AA Rabbit Polyclonal Antibody

Product Images

To detect hPDGF-AA by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Human PDGF-AA (TA328414) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hPDGF-AA.

• 

  To detect hPDGF-AA by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Human PDGF-AA (TA328414) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hPDGF-AA.

Specifications

Product Data

• Applications: ELISA, IHC
• Recommended Dilution: WB: 0.1-0.2ug/mL, ELISA: 0.25-2ug/mL, IHC: 0.25ug/mL - 1mg/mL
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: E.coli derived Recombinant Human PDGF-AA
• Formulation: A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.
• Purification: Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hPDGF-AA. Anti-Human PDGF-AA specific antibody was purified by affinity chromatography employing immobilized hPDGF-AA matrix.
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: platelet derived growth factor subunit A
• Database Link:
  NP_148983
  Entrez Gene 5154 Human
  UniProt ID P04085
• Synonyms: PDGF-A; PDGF1
• Note: Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of hPDGF-AA (5.0 ng/ml), a concentration of 0.13-0.20 <=ug/ml of this antibody is required.

Reference Data

• Protein Families: Druggable Genome
• Protein Pathways: Cytokine-cytokine receptor interaction, Focal adhesion, Gap junction, Glioma, MAPK signaling pathway, Melanoma, Pathways in cancer, Prostate cancer, Regulation of actin cytoskeleton